Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
Public ClinicalTrials.gov record NCT00628095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF CE-224,535, AN ANTAGONIST OF THE P2X7 RECEPTOR, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN SUBJECTS WHO ARE INADEQUATELY CONTROLLED ON METHOTREXATE
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis
Study identification
- NCT ID
- NCT00628095
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 7, 2008 (Actual)
- Primary completion
- Feb 4, 2009 (Actual)
- Completion
- Feb 4, 2009 (Actual)
- Last update posted
- Apr 4, 2022
2008 – 2009
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Arthritis & Rheumatology Associates, P.C. | Mesa | Arizona | 85202 | — |
| Omega Research Consultants LLC | DeBary | Florida | 32713 | — |
| Florida Arthritis Center | Lake Mary | Florida | 32746 | — |
| Tampa Medical Group, PA | Tampa | Florida | 33614 | — |
| American Health Network | Avon | Indiana | 46123 | — |
| Best Clinical Trials, LLC (Administrative Only) | New Orleans | Louisiana | 70115 | — |
| George Stanley Walker, MD | New Orleans | Louisiana | 70115 | — |
| Majid Abdul Jawad, MD | New Orleans | Louisiana | 70115 | — |
| The Arthritis and Osteoporosis Center of Maryland | Frederick | Maryland | 21702 | — |
| University Physicians | Columbia | Missouri | 65203 | — |
| University of Missouri-Columbia | Columbia | Missouri | 65212 | — |
| Arthritis Center of Reno | Reno | Nevada | 89502 | — |
| New Horizons Clinical Research | Cincinnati | Ohio | 45242 | — |
| Arthritis Northwest | Spokane | Washington | 99204-2336 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00628095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2022 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00628095 live on ClinicalTrials.gov.